These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9437293)

  • 1. Use of statins. Health authorities must work with clinicians to target statins.
    Wakeman AP; Leach RH
    BMJ; 1997 Dec; 315(7122):1618. PubMed ID: 9437293
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of statins. Adequacy of SMAC's statement should be judged by clinicians, not health economists.
    Enoch P
    BMJ; 1997 Dec; 315(7122):1615. PubMed ID: 9437285
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of statins. In New Zealand, subsidy of statins is limited to particular groups of patients.
    Bennett W; McNee W; Metcalfe S; Wright JM
    BMJ; 1997 Dec; 315(7122):1616. PubMed ID: 9437288
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of statins. Evidence on effectiveness is stronger for statins than for other treatments.
    Wallis EJ; Ramsay LE; Yeo WW; Jackson PR; Pickin M; Haq IU
    BMJ; 1997 Dec; 315(7122):1618-9. PubMed ID: 9437295
    [No Abstract]   [Full Text] [Related]  

  • 5. The human and economic costs of undertreatment with statins.
    Durrington P
    Int J Clin Pract; 2002 Jun; 56(5):357-68. PubMed ID: 12137445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price?
    Szucs TD
    Eur Heart J; 1998 Oct; 19 Suppl M():M22-8. PubMed ID: 9821013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of statins. Glasgow has already produced strategy for treatment.
    McMurray J; McGuire A; Raikou M; Morrison C
    BMJ; 1997 Dec; 315(7122):1617-8. PubMed ID: 9437292
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of statins. Faculty's advice does refer to cost effectiveness.
    Davis AM
    BMJ; 1997 Dec; 315(7122):1617. PubMed ID: 9437290
    [No Abstract]   [Full Text] [Related]  

  • 9. Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.
    Ritchie LD
    Br J Gen Pract; 2000 Sep; 50(458):693-5. PubMed ID: 11050781
    [No Abstract]   [Full Text] [Related]  

  • 10. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statines for all or individualized lipid lowering therapy?].
    Parhofer K
    MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of statins. Results of different studies differed greatly.
    Mikhailidis DP; Winder AF
    BMJ; 1997 Dec; 315(7122):1617. PubMed ID: 9437291
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of statins. Sheffield tables have shortcomings.
    Betteridge J; Shepherd J; Thompson G
    BMJ; 1997 Dec; 315(7122):1619. PubMed ID: 9437296
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
    Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
    Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of statins. Trent Institute's Research Working Group has produced guidance for purchasers.
    Akehurst RL
    BMJ; 1997 Dec; 315(7122):1615-6. PubMed ID: 9437286
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of statins. Other, cheaper and simpler, measures should be tried first.
    Sheridan P; Savege P; Silverman S
    BMJ; 1997 Dec; 315(7122):1616. PubMed ID: 9437287
    [No Abstract]   [Full Text] [Related]  

  • 17. [The secondary prevention of coronary disease: ACE inhibitors, adrenergic beta-blockers and statins for everyone? The arguments con].
    Simões L; Guimarães J; Fontes JP
    Rev Port Cardiol; 2000 Jan; 19(1):107-13. PubMed ID: 10731796
    [No Abstract]   [Full Text] [Related]  

  • 18. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of statins. Guidelines need to concentrate on reducing overall cardiovascular risk.
    Wierzbicki AS; Reynolds TM
    BMJ; 1997 Dec; 315(7122):1616-7. PubMed ID: 9437289
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid-lowering drugs: use and expenditure in Portugal (1995-2004).
    Teixeira IJ; Escoval A; Schiappa M
    Rev Port Cardiol; 2007 May; 26(5):475-93. PubMed ID: 17691275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.